Chicago, IL, United States of America

Guoyao Xia

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guoyao Xia: Innovator in Neurodegenerative Disease Treatment

Introduction

Guoyao Xia is a notable inventor based in Chicago, IL, who has made significant contributions to the field of pharmaceuticals. His work primarily focuses on developing treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). With a keen interest in innovative compounds, Xia has dedicated his research to improving the lives of those affected by these debilitating conditions.

Latest Patents

Guoyao Xia holds a patent for "Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis." This invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions for treating subjects with ALS and other neurodegenerative diseases. The patent also outlines methods for preparing these inventive PYT compounds, showcasing Xia's commitment to advancing medical science.

Career Highlights

Throughout his career, Guoyao Xia has worked with esteemed institutions, including Northwestern University and Cambria Pharmaceuticals, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Guoyao Xia's notable coworkers include Donald R. Kirsch and Radhia Benmohamed. Their collaborative efforts have further enhanced the research and development of innovative treatments for neurodegenerative diseases.

Conclusion

Guoyao Xia's contributions to the field of pharmaceuticals, particularly in the treatment of ALS, highlight his dedication to innovation and improving patient outcomes. His work continues to inspire future advancements in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…